Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

[Abstract] The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1)to evaluate the impact of CTCL on patient qual...

ver descrição completa

Detalhes bibliográficos
Autores: Navarro Matilla, B, Ortiz Romero, P L, Pujol Vallverdú, R M, Combalia Escudero, A, Zapata Paz, I, González Barca, E, Muniesa Montserrat, C, Morillo Andújar, M, Pérez Ferriols, A, Román Curto, C, Fernández de Misa Cabrera, R, Hospital Gil, M, Marín Niebla, A, Rios Rull, P J, de la Cruz Vicente, F, Izu Belloso, R M, Martín García-Sancho, A, Parera-Amer, Maria Elisabet, Córdoba Mascuñano, R, Ramón Quiles, M D, Saus Carreres, A, del Campo Garcia, Raquel, Machan, S, Viguera Ester, P, Blanco Garnelo, J
Tipo de documento: artigo
Data de publicação:2024
País:España
Recursos:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositório:Docusalut
Idioma:inglês
OAI Identifier:oai:docusalut.com:20.500.13003/20863
Acesso em linha:https://hdl.handle.net/20.500.13003/20863
Access Level:Acceso aberto
Palavra-chave:Male
Quality of Life
Spain
Skin Neoplasms
Adult
Female
Mycosis Fungoides
Humans
Sezary Syndrome
Middle Aged
Lymphoma, T-Cell, Cutaneous
Linfoma Cutáneo de Células T
Micosis Fungoide
Humanos
Persona de Mediana Edad
Calidad de Vida
Femenino
Síndrome de Sézary
Neoplasias Cutáneas
Adulto
España
Masculino
Descrição
Resumo:[Abstract] The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1)to evaluate the impact of CTCL on patient quality of life, and 2)to evaluate the costs associated with the disease. This article reports the results of the cost analysis. We estimated the cost of treating CTCL over a period of 1year from the perspective of the Spanish National Health System. Twenty-three dermatologists and hematologists from 15 public hospitals analyzed data for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS). A total of 141 patients (57.4% male) with a mean age of 63.6 years (95%CI: 61.4-65.7 years) were included. The mean direct annual cost of treating CTCL was €34,214 per patient. The corresponding costs by stage were €11,952.47 for stageI disease, €23,506.21 for stageII disease, €38,771.81 for stageIII disease, and €72,748.84 for stageIV disease. The total direct annual cost of treating MF/SS in public hospitals in Spain was estimated at €78,301,171; stageI disease accounted for 81% of all costs, stageII for 7%, and stagesIII andIV for 6% each. The MICADOS study offers an accurate picture of the direct cost of treating CTCL in patients with MF/SS in Spain and shows that costs vary significantly according to disease stage. Patient-borne and indirect costs should be analyzed in future studies.

Registros relacionados